Besides the aforementioned decreases in MMP-14 and, subsequently, MMP-2 levels, statins also trigger a decline in the expression of TIMP-2 and also TIMP-1, restoring the MMP-TIMP balance and reducing the progression and metastatic rates of HCC in a preclinical model [68]. This evidence concerns the gene MMP2 and hepatocellular carcinoma.